



**24 February 2025** 

#### India | Equity Research | Company Update

### **Solar Industries**

Defence

## The show has just begun

We recently hosted the management of Solar Industries (SOIL) for an interaction with investors. Key points: 1) Defence and exports & overseas segments could shepherd growth over the next five years; 2) EBITDA margin may sustain at ~27% over the next few years; 3) capex intensity could significantly rise in next five years; 4) favourable macro environment in ammunitions may be a significant tailwind; and 5) focus on indigenisation remains intact. We believe the recent stock price correction provides a good entry point in SOIL. Going forward, growth is likely to be driven by high-margin segments, and SOIL could go further up in value chain to platforms from materials. Retain BUY with an unchanged TP of INR 13,720 on 60x FY27E EPS.

## The landscape has widened

In our view, it is a wrong notion that Pinaka is the ultimate glory for SOIL. The company has recently executed MoU with the Government of Maharashtra for setting up an Anchor Mega Defence & Aerospace project in Nagpur at an investment of INR 127bn. We believe the revenue potential of such a project could be INR 250bn p.a., placing SOIL as one of the top players in defence ecosystem in India. Furthermore, the company is moving up the defence value chain from materials to platforms, integrating its capabilities developed over the years. We believe this will open significant export opportunities for the company, besides enhancing its presence in domestic defence ecosystem. Additionally, the reliance on ToT from DRDO and strong track record of inhouse R&D have resulted in SOIL developing products with a significantly higher level of indigenised content.

#### Next five years are likely to be busy

Recently, the company has changed the name of its fully owned subsidiary engaged in defence business from 'Economic Explosives Limited' to 'Solar Defence and Aerospace Limited' showing its sharpened focus on defence and aerospace. In our view, the capex over the next five years is likely to be INR 130-150bn in both defence and non-defence (exports & overseas) domains. This may be funded mainly through internal accruals. Besides, the company is expected to be in net cash position by end-FY25, hence, there is sufficient headroom in its balance sheet to take incremental debt.

## **Financial Summary**

| Y/E March (INR mn) | FY24A  | FY25E  | FY26E  | FY27E    |
|--------------------|--------|--------|--------|----------|
| Net Revenue        | 60,695 | 73,011 | 93,945 | 1,11,611 |
| EBITDA             | 13,692 | 19,398 | 26,039 | 31,116   |
| EBITDA Margin (%)  | 22.6   | 26.6   | 27.7   | 27.9     |
| Net Profit         | 8,356  | 12,688 | 17,426 | 20,692   |
| EPS (INR)          | 92.3   | 140.2  | 192.6  | 228.7    |
| EPS % Chg YoY      | 7.8    | 47.4   | 38.0   | 19.7     |
| P/E (x)            | 91.5   | 62.1   | 45.0   | 37.6     |
| EV/EBITDA (x)      | 60.7   | 42.9   | 31.7   | 26.3     |
| RoCE (%)           | 23.8   | 27.3   | 30.2   | 28.5     |
| RoE (%)            | 30.6   | 35.2   | 36.2   | 32.0     |

#### **Amit Dixit**

amit.dixit@icicisecurities.com +91 22 6807 7289

### **Mohit Lohia**

mohit.lohia@icicisecurities.com

#### **Pritish Urumkar**

Pritish.urumkar@icicisecurities.com

#### **Market Data**

| Market Cap (INR)    | 801bn         |
|---------------------|---------------|
| Market Cap (USD)    | 9,239mn       |
| Bloomberg Code      | SOIL IN       |
| Reuters Code        | SLIN.BO       |
| 52-week Range (INR) | 13,300 /6,623 |
| Free Float (%)      | 27.0          |
| ADTV-3M (mn) (USD)  | 12.1          |

| Price Performance (%) | 3m     | 6m     | 12m  |
|-----------------------|--------|--------|------|
| Absolute              | (11.3) | (13.7) | 32.3 |
| Relative to Sensex    | (8.9)  | (6.8)  | 28.6 |

| ESG Score   | 2023 | 2024 | Change |
|-------------|------|------|--------|
| ESG score   | 59.4 | 60.3 | 0.9    |
| Environment | 34.7 | 43.0 | 8.3    |
| Social      | 69.8 | 68.1 | (1.7)  |
| Governance  | 69.6 | 70.8 | 1.2    |

Note - Score ranges from 0 - 100 with a higher score indicating higher ESG disclosures.

Source: SES ESG, I-sec research

#### **Previous Reports**

07-02-2025: Company Update 07-02-2025: Q3FY25 results review



## **Outlook: Shifting gears**

Rather than estimating the margin of SOIL based on explosives and ammonium nitrate spread, it is prudent to value the company based on future growth verticals- defence and aerospace. Based on its current orderbook, initiatives being taken by the company and potential in the ecosystem, we reckon, defence revenue could grow over 4x from FY25 level over the next five years. Also, SOIL has plans to make the value chain robust by backward integration, forward integration and developing new products in non-defence domain. As per our analysis, EBITDA CAGR (FY22-FY27E) is likely to be 33% and margins are expected to hover above 27% as the proportion of defence and exports & overseas increases. Also, we see a long runway for 25% plus growth in EBITDA as the benefits of capex fructify in future. Maintain **BUY** on SOIL with an unchanged TP of INR 13,720 on 60x FY27E EPS.

### **Key risks**

- Slower than expected ordering in defence.
- Further fall in ammonium nitrate price leading to negative price-cost spread.
- Slow traction in construction and infrastructure segments.




## Takeaway #1: Defence likely to be 33% of revenue by FY30E

We prefer to take a medium-term view of SOIL stock as capex is being sped up. Compared to gross block of INR 24bn at end-FY24, the company is investing INR 12bn in FY25 and based on its current plans, the investment over the next five years (FY26-30) is likely to be INR 150bn. As a result, we expect revenue to be equally split among exports & overseas, defence and others. Of these three buckets, we believe that the former two yield better margins, and hence, EBITDA margin is also expected to improve from current 25-27% levels.

The biggest shift in revenue mix is coming from defence, whose share is expected to increase from <2% in FY18 to >33% by FY30E.

Exhibit 1: Revenue split across the segments



Source: I-Sec research, Company data

## Takeaway #2: From Materials to Platforms in Defence

In defence value pyramid, there are hardly companies in India present across different verticals. Furthermore, the level of indigenisation is usually lower at the top-end of the pyramid, leading to lesser margins. In case of SOIL, the products are expected to be across the value chain and products/solutions are co-developed or ToT is sourced from DRDO. The company has been taking significant efforts to develop in-house capabilities. Some of the recent developments include:

- Materials: Development of SEBEX-3, SITBEX-1 and SIMEX-4 explosives.
- **Sub-systems**: Developed guided bombs compatible with IAF aircraft of both NATO and Russian types. The bombs are designed to be equipped on the French Mirage 2000 or potentially on a Sukhoi-30.
- **Platforms**: Developed counter drone system- Bhargavastra. The initial trails have been successful.
- Set up a 1,000 nos. p.a. drone manufacturing facility capable of producing various types of drones, including loitering munitions and unmanned aerial vehicles (UAVs). The company has already supplied the INR 2.1bn order of Nagastra-I.
- Commissioned the indigenous chaffs and flares factory in Nagpur.



Platforms Rockets & Missiles, Counter drone systems, Loitering munitions

Subsystems Ammunition ,Air bombs, Warheads, Space Applications

MMHG, Pyros and Fuses

Components

High Energy Materials, Propellants

Exhibit 2: SOIL's offerings are spread across the Defence pyramid

Source: I-Sec research

Over the next couple of years, the company is expected to focus on both loitering munitions and weaponised drones (hexacopter), anti-drone missiles, as well as bombs and warheads for the armed forces. We expect the potential of loitering munitions to be even higher than Pinaka.

After securing domestic Pinaka order (SOIL's share: INR 60bn), we expect orders from export markets as well. Besides, SOIL is likely to participate in the development of enhanced range and guided Pinaka in future, having developed Mahashwetastra already.

Current defence orderbook stands at INR 110bn, of which INR 44-45bn are export orders to be executed within next 3-4 years. Given the global shortage of ammunition, we expect more orders for SOIL for high-energy explosives in near future. Besides, the company has all the components for manufacturing shells in-house, such as BMCS, propellent, explosives and fuses. Hence, we believe the company could venture into 155mm shell manufacturing in the near future.

We peg defence revenue at INR 14-15bn in FY25E and INR 27bn in FY26E. Based on the orderbook and initiatives being pursued, we see revenue of INR 60-65bn from defence by FY30E.

### Takeaway #3: Non-defence exports to remain a solid pillar

SOIL has been focusing on non-defence exports in construction and mining domains worldwide. We expect this segment to contribute 35-40% of revenue by FY30E, similar to 39% in FY25E. Going ahead, the company is focusing on forward integration, such as acquisition of ProBlast Blasting Solutions in South Africa. We also expect the company to deepen its global footprint by backward integration and further expansion of its reach in key countries. All its overseas subsidiaries are making profit now and we expect the incremental contribution to increase.



## Takeaway #4: 25 years of growth likely to get further wings

In case of SOIL, the growth across key parameters has been continuous and sustained. Despite EBITDA rising 4x in FY22 compared to FY12 levels, we see incremental EBITDA growth at 33% CAGR from FY22-27E led by higher share of defence and exports & overseas business segments.

**Exhibit 3: Financials across periods** 

| (INR mn)       | FY02 | FY07  | FY12  | FY17   | FY22   | FY27E    |
|----------------|------|-------|-------|--------|--------|----------|
| Revenue        | 591  | 2,082 | 9,676 | 15,800 | 39,476 | 1,11,611 |
| EBITDA         | 104  | 318   | 1,710 | 3,258  | 7,348  | 30,384   |
| PAT            | 67   | 192   | 1,012 | 1,865  | 4,413  | 21,008   |
| EPS- INR/share | 0.7  | 2.1   | 11.2  | 20.7   | 49.0   | 233.4    |

Source: I-Sec research, Company data

It is noteworthy that EPS growth through to FY27 is expected to be much higher than FY12-17 and FY17-22 periods, despite a high base.

Exhibit 4: 5-yr CAGR in past 25 years

| CAGR (%) | FY02-FY07 | FY07-FY12 | FY12-FY17 | FY17-FY22 | FY22-FY27E |
|----------|-----------|-----------|-----------|-----------|------------|
| Revenue  | 28.7%     | 36.0%     | 10.3%     | 20.1%     | 23.1%      |
| EBITDA   | 25.0%     | 40.0%     | 13.8%     | 17.7%     | 32.8%      |
| PAT      | 23.4%     | 39.4%     | 13.0%     | 18.8%     | 36.6%      |
| EPS      | 23.4%     | 39.4%     | 13.0%     | 18.8%     | 36.6%      |

Source: I-Sec research, Company data

Going ahead, we expect EBITDA and PAT margins to improve to 24.7% and 15% on average for FY22-27E and further to 28.1% and 19.6%, respectively, on average over FY28-30E.

**Exhibit 5: Margins across periods** 

| (%)              | FY02-<br>FY06 | FY07-<br>FY11 | FY12-<br>FY16 | FY17-<br>FY21 | FY22-<br>FY27E | FY28E-<br>FY30E |
|------------------|---------------|---------------|---------------|---------------|----------------|-----------------|
| EBITDA<br>margin | 18.7          | 17.0          | 18.5          | 20.8          | 24.7           | 28.1            |
| PAT margin       | 10.5          | 10.4          | 10.7          | 11.4          | 15.0           | 19.6            |

Source: I-Sec research, Company data

### Takeaway #5: Capex likely to accelerate; Revenue to follow

As a result of significant investments planned in both defence and non-defence domains, we expect capex to accelerate significantly. It is noteworthy that total capex from FY02 to FY24 was INR 34bn. Revenue at end-FY24 was INR 60.9bn, implying fixed asset (gross) turnover at 2x. Going forward, the investment over FY26-30E is likely at INR 150bn, and hence, revenue potential in future may be much higher.

We expect almost INR 100bn of incremental capex over the next five years to be met through internal accruals with debt of INR 50bn to take care of the rest.

Exhibit 6: Capex intensity likely to pick up

| (INR mn) | FY02-FY06 | FY07-FY11 | FY12-FY16 | FY17-FY21 | FY21-FY27E | FY28E-FY30E |
|----------|-----------|-----------|-----------|-----------|------------|-------------|
| Capex    | -1,434    | -1,883    | -6,524    | -12,511   | -62,215    | -1,10,000   |


Source: I-Sec research, Company data



## Takeaway #6: Correlation with Ammonium Nitrate prices is irrelevant

In our view, street has been monitoring and extrapolating SOIL's performance on the basis of ammonium nitrate price movement. Historically, there has been significant dependence of explosives realisation on ammonium nitrate prices.


Exhibit 7: Correlation between Ammonium Nitrate and Explosive realisation



Source: I-Sec research, Bloomberg, Company data

In case of SOIL, however, the correlation between EBITDA margin and ammonium nitrate prices is not there, particularly since defence and exports & overseas earnings have taken off. Despite ammonium nitrate prices moderating to near historical average, margins still remain high.

**Exhibit 8: EBITDA margins compared to Ammonium Nitrate index** 




Source: I-Sec research, Bloomberg, Company data

Even EBITDA/te is much higher than the past owing to change in product mix. Going ahead, as defence mix (and more so from platforms) improves, EBITDA/te may progressively get more isolated from barely ammonium nitrate price movement.



## Exhibit 9: Consolidated EBITDA/te compared to Ammonium Nitrate index



Source: I-Sec research, Company data, Bloomberg



### How we differ from the consensus?

We are in line with consensus on revenue. However, on margin front, we are higher as we have taken cognisance of defence revenue increasing. In Q3FY25, SOIL delivered consolidated EBITDA margin of 26.7% (9MFY25: 26.4%). In Q4E, we expect the revenue from defence to increase further, and hence, EBITDA margin is expected to remain robust. In our view, consensus estimates for FY25 are likely to be revised upwards.

Similarly, for FY26/27E, consensus is expecting margins to be lower or in similar range as Q3FY25 despite higher proportion of revenue from defence. Our FY26/27E EBITDA is 6%/ 4% ahead of consensus, respectively. On EPS, we are 13%/7% ahead for FY26/27E, respectively.

Exhibit 10: Our estimates are ahead of consensus

| (INR mn)          |        | EC estimates | 5        |        | Consensus |          | % diff (IS | EC and Conse | ensus) |
|-------------------|--------|--------------|----------|--------|-----------|----------|------------|--------------|--------|
| (,                | FY25E  | FY26E        | FY27E    | FY25E  | FY26E     | FY27E    | FY25E      | FY26E        | FY27E  |
| Revenue           | 73,011 | 93,945       | 1,11,611 | 75,219 | 92,809    | 1,12,283 | -2.9       | 1.2          | -0.6   |
| EBITDA            | 19,398 | 26,039       | 31,116   | 19,490 | 24,468    | 29,978   | -0.5       | 6.4          | 3.8    |
| EBITDA margin (%) | 26.6   | 27.7         | 27.9     | 25.9   | 26.4      | 26.7     |            |              |        |
| PAT               | 12,688 | 17,426       | 20,692   | 12,240 | 15,466    | 19,299   | 3.7        | 12.7         | 7.2    |
| PAT margin (%)    | 17.4   | 18.5         | 18.5     | 16.3   | 16.7      | 17.2     |            |              |        |
| EPS (INR/share)   | 140.2  | 192.6        | 228.7    | 135.3  | 170.9     | 213.3    | 3.7        | 12.7         | 7.2    |
| RoE (%)           | 32.5   | 32.6         | 28.9     | 31.8   | 30.3      | 28.8     |            |              |        |

Source: I-Sec research, Bloomberg

## Valuations: The stock is trading at 36% discount to its peak valuation

At CMP, SOIL stock is trading at 36% discount to its peak valuation of 66x EPS (2 yr fwd). Further, the current P/E of 42.2x FY26E EPS is 1.5x deviation above the mean. In our view, SOIL's RoE is expected to improve to 30% plus, through to FY27E compared to 23% on average over FY15-24E. Also, in view of the growth prospects - EPS growth at 27% CAGR through to FY30E (from FY24E levels), the premium to mean is justified.

Exhibit 11: SOIL is trading at significant discount to its peak



Source: I-Sec research, Bloomberg



Exhibit 12: SOIL Q3FY25 standalone performance review

| (INR mn)                   | Q3FY25 | Q3FY24 | Chg YoY (%) | Q2FY25 C | hg QoQ (%) | FY24   | FY23   | Chg YoY (%) |
|----------------------------|--------|--------|-------------|----------|------------|--------|--------|-------------|
| Net Sales                  | 12,072 | 9,023  | 33.8        | 9,055    | 33.3       | 37,175 | 41,623 | (10.7)      |
| Total Income               | 12,072 | 9,023  | 33.8        | 9,055    | 33.3       | 37,175 | 41,623 | (10.7)      |
| Expenditure                |        |        |             |          |            |        |        |             |
| Change in Stock            | 187    | 144    |             | (113)    |            | 202    | (55)   |             |
| Consumption of Material    | 6,128  | 4,637  | 32.2        | 4,515    | 35.7       | 20,486 | 27,968 | (26.8)      |
| Purchase of traded goods   | 753    | 855    | (11.9)      | 622      | 21.1       | 2,326  | 2,136  | 8.9         |
| Employee Costs             | 564    | 482    | 17.1        | 528      | 6.9        | 1,855  | 1,454  | 27.6        |
| Other Expenditure          | 1,544  | 986    | 56.6        | 1,192    | 29.5       | 3,959  | 3,832  | 3.3         |
| Total Expenditure          | 9,177  | 7,104  | 29.2        | 6,744    | 36.1       | 28,829 | 35,334 | (18.4)      |
| EBITDA                     | 2,896  | 1,919  | 50.9        | 2,311    | 25.3       | 8,347  | 6,288  | 32.7        |
| EBITDA Margin              | 24.0   | 21.3   |             | 25.5     |            | 22.5   | 15.1   |             |
| Other Income               | 118    | 177    | (33.3)      | 316      | (62.7)     | 583    | 558    | 4.5         |
| Depreciation               | 191    | 161    | 18.4        | 179      | 6.9        | 634    | 570    | 11.1        |
| Interest and Finance Costs | 79     | 77     | 1.9         | 67       | 17.1       | 296    | 276    | 7.3         |
| Exceptional Items          | -      | -      |             | -        |            | -      | -      |             |
| PLT                        | 2,744  | 1,857  | 47.7        | 2,382    | 15.2       | 8,001  | 6,001  | 33.3        |
| Tax Expense                | 700    | 474    | 47.6        | 580      |            | 2,038  | 1,547  | 31.7        |
| MI                         | -      | -      |             | -        |            | -      | -      |             |
| PAT                        | 2,044  | 1,383  | 47.8        | 1,802    | 13.4       | 5,963  | 4,454  | 33.9        |
| OCI                        | -      | (2)    |             | 94       |            | -      | -      |             |
| TCI                        | 2,044  | 1,381  |             | 1,895    |            | 5,963  | 4,454  |             |

Source: I-Sec research, Company data

Exhibit 13: SOIL Q3FY25 consolidated performance review

| (INR mn)                   | Q3FY25 | Q3FY24 | Chg YoY (%) | Q2FY25 C | hg QoQ (%) | FY24    | FY23   | Chg YoY (%) |
|----------------------------|--------|--------|-------------|----------|------------|---------|--------|-------------|
| Net Sales                  | 19,731 | 14,291 | 38.1        | 17,158   | 15.0       | 60,695  | 69,225 | (12.3)      |
| Other Operating Income     | -      | -      |             | -        |            | -       | -      |             |
| Total Income               | 19,731 | 14,291 | 38.1        | 17,158   | 15.0       | 60,695  | 69,225 | (12.3)      |
| Expenditure                |        |        |             |          |            |         |        |             |
| Change in Stock            | 132    | (128)  |             | (508)    |            | 836     | (374)  |             |
| Consumption of Material    | 8,851  | 6,345  | 39.5        | 6,815    | 29.9       | 27,100  | 36,215 | (25.2)      |
| Purchase of traded goods   | 1,304  | 1,299  | 0.4         | 2,123    | (38.6)     | 4,026   | 7,583  | (46.9)      |
| Employee Costs             | 1,507  | 1,115  | 35.2        | 1,447    | 4.1        | 4,335   | 3,527  | 22.9        |
| Other Expenditure          | 2,672  | 2,098  | 27.4        | 2,834    | (5.7)      | 10,707  | 9,385  | 14.1        |
| Total Expenditure          | 14,465 | 10,729 | 34.8        | 12,711   | 13.8       | 47,003  | 56,336 | (16.6)      |
| EBITDA                     | 5,265  | 3,562  | 47.8        | 4,448    | 18.4       | 13,692  | 12,889 | 6.2         |
| EBITDA Margin (%)          | 26.7   | 24.9   |             | 25.9     |            | 22.6    | 18.6   |             |
| Adjusted EBITDA            | 5,446  | 4,255  | 28.0        | 4,535    | 20.1       |         |        |             |
| Other Income               | 95     | 109    | (12.6)      | 305      | (68.7)     | 445     | 315    | 41.1        |
| Depreciation               | 474    | 386    | 22.8        | 436      | 8.7        | 1,434   | 1,282  | 11.8        |
| Interest and Finance Costs | 305    | 283    | 7.8         | 297      | 2.6        | 1,094   | 904    | 21.0        |
| Exceptional Items          | -      | -      |             | -        |            | -       | -      |             |
| PLT                        | 4,582  | 3,003  | 52.6        | 4,019    | 14.0       | 11,609  | 11,019 | 5.4         |
| Tax Expense                | 1,216  | (74)   | (1,754.6)   | 1,032    | 17.9       | 1,327   | 2,904  | (54.3)      |
| -Current Tax               | 1,178  | -      |             | 1,051    | 12.1       | 1,540   | 3,140  |             |
| -Deferred Tax              | 38     | (74)   |             | (19)     |            | (212)   | (236)  |             |
| -Prior Period Taxes        | -      | -      |             | -        |            | -       | -      |             |
| PAT Lefore MI              | 3,365  | 2,159  |             | 2,987    | 12.7       | 10,282  | 8,114  |             |
| MI                         | 10     | 186    |             | 51       | (81.2)     | 297     | 540    |             |
| PAT                        | 3,375  | 1,973  | 71.1        | 3,038    | 11.1       | 9,985   | 7,575  | 31.8        |
| OCI                        | (341)  | (551)  |             | (77)     |            | (1,445) | (289)  |             |
| TCI                        | 3,034  | 1,608  |             | 2,961    |            | 8,541   | 7,286  |             |

Source: Company data, I-Sec research



Exhibit 14: SOIL Operational performance review

| (INR mn)                | Q3FY25   | Q3FY24   | %Chg YoY | Q2FY25   | %Chg QoQ |
|-------------------------|----------|----------|----------|----------|----------|
| Explosive               |          |          |          |          |          |
| Quantity (te)           | 1,55,222 | 1,54,421 | 0.5      | 1,06,057 | 46.4     |
| Blended Realisation/te  | 44,754   | 44,805   | (0.1)    | 50,379   | (11.2)   |
| Blended Gross Margin/te | 32,236   | 21,928   | 47.0     | 38,010   | (15.2)   |
| Blended EBITDA/te       | 18,655   | 12,427   | 50.1     | 21,792   | (14.4)   |

Source: I-Sec research, Company data

Exhibit 15: SOIL Quarterly revenue breakdown


| (INR mn)           | Q3FY25 | Q3FY24 | %Chg YoY | Q2FY25 | %Chg QoQ |
|--------------------|--------|--------|----------|--------|----------|
| Sales breakdown    | 19,730 | 14,290 | 38.1     | 17,160 | 15.0     |
| CIL                | 2,590  | 2340   | 10.7     | 1,690  | 53.3     |
| Institutional      | 2,780  | 2450   | 13.5     | 2,240  | 24.1     |
| Housing & Infra    | 2,570  | 2510   | 2.4      | 1,910  | 34.6     |
| Exports & Overseas | 7,580  | 6240   | 21.5     | 7,990  | (5.1)    |
| Defence            | 4,090  | 620    | 559.7    | 3,220  | 27.0     |
| Others             | 120    | 130    | (7.7)    | 110    | 9.1      |

Source: Company data, I-Sec research

**Exhibit 16: Shareholding pattern** 

| %                       | Jun'24 | Sep'24 | Dec'24 |
|-------------------------|--------|--------|--------|
| Promoters               | 73.2   | 73.2   | 73.2   |
| Institutional investors | 20.2   | 20.2   | 20.0   |
| MFs and others          | 12.3   | 11.7   | 11.7   |
| Fls/Banks               | 0.3    | 0.7    | 1.0    |
| FIIs                    | 7.6    | 7.8    | 7.2    |
| Others                  | 6.6    | 6.6    | 6.8    |

Exhibit 17: Price chart



Source: Bloomberg, I-Sec research

Source: Bloomberg, I-Sec research



# **Financial Summary**

### **Exhibit 18: Profit & Loss**

(INR mn, year ending March)

|                                    | FY24A  | FY25E  | FY26E  | FY27E    |
|------------------------------------|--------|--------|--------|----------|
| Net Sales                          | 60,695 | 73,011 | 93,945 | 1,11,611 |
| Operating Expenses                 | 15,041 | 15,906 | 16,557 | 18,263   |
| EBITDA                             | 13,692 | 19,398 | 26,039 | 31,116   |
| EBITDA Margin (%)                  | 22.6   | 26.6   | 27.7   | 27.9     |
| Depreciation & Amortization        | 1,434  | 1,679  | 1,823  | 2,185    |
| EBIT                               | 12,258 | 17,719 | 24,216 | 28,932   |
| Interest expenditure               | 1,094  | 1,064  | 1,012  | 1,012    |
| Other Non-operating Income         | 445    | 758    | 812    | 823      |
| Recurring PBT                      | 11,609 | 17,413 | 24,016 | 28,743   |
| Profit / (Loss) from<br>Associates | -      | -      | -      | -        |
| Less: Taxes                        | 2,861  | 4,519  | 6,225  | 7,450    |
| PAT                                | 8,749  | 12,894 | 17,791 | 21,293   |
| Less: Minority Interest            | 393    | 206    | 364    | 601      |
| Extraordinaries (Net)              | -      | -      | -      | -        |
| Net Income (Reported)              | 8,749  | 12,894 | 17,791 | 21,293   |
| Net Income (Adjusted)              | 8,356  | 12,688 | 17,426 | 20,692   |

Source Company data, I-Sec research

#### **Exhibit 19: Balance sheet**

(INR mn, year ending March)

|                             | FY24A  | FY25E   | FY26E  | FY27E  |
|-----------------------------|--------|---------|--------|--------|
| Total Current Assets        | 24,349 | 25,269  | 34,111 | 46,387 |
| of which cash & cash eqv.   | 2,873  | (1,034) | 5,423  | 12,295 |
| Total Current Liabilities & | 7,546  | 8,407   | 10,358 | 11,952 |
| Provisions                  | 7,540  | 0,407   | 10,550 | 11,332 |
| Net Current Assets          | 16,803 | 16,862  | 23,753 | 34,436 |
| Investments                 | 3,699  | 3,699   | 3,699  | 3,699  |
| Net Fixed Assets            | 19,607 | 29,929  | 40,106 | 49,921 |
| ROU Assets                  | -      | -       | -      | -      |
| Capital Work-in-Progress    | 2,874  | 2,874   | 2,874  | 2,874  |
| Total Intangible Assets     | 298    | 298     | 298    | 298    |
| Other assets                | 3,819  | 3,819   | 3,819  | 3,819  |
| Deferred Tax Assets         | 1,602  | 1,602   | 1,602  | 1,602  |
| Total Assets                | 48,702 | 59,083  | 76,151 | 96,649 |
| Liabilities                 |        |         |        |        |
| Borrowings                  | 12,452 | 10,617  | 10,617 | 10,617 |
| Deferred Tax Liability      | 1,978  | 1,978   | 1,978  | 1,978  |
| provisions                  | -      | -       | -      | -      |
| other Liabilities           | -      | -       | -      | -      |
| Equity Share Capital        | 181    | 181     | 181    | 181    |
| Reserves & Surplus          | 32,875 | 44,884  | 61,588 | 81,485 |
| Total Net Worth             | 33,056 | 45,065  | 61,769 | 81,666 |
| Minority Interest           | 1,217  | 1,422   | 1,787  | 2,387  |
| Total Liabilities           | 48,702 | 59,083  | 76,151 | 96,649 |

Source Company data, I-Sec research

## **Exhibit 20: Quarterly trend**

(INR mn, year ending March)

|                     | Mar-24 | Jun-24 | Sep-24 | Dec-24 |
|---------------------|--------|--------|--------|--------|
| Net Sales           | 16,107 | 16,948 | 17,158 | 19,731 |
| % growth (YOY)      | 12.7   | (72.1) | 1.2    | 15.0   |
| EBITDA              | 3,537  | 4,494  | 4,448  | 5,265  |
| Margin %            | 22.0   | 26.5   | 25.9   | 26.7   |
| Other Income        | 177    | 243    | 305    | 95     |
| Extraordinaries     | -      | -      | -      | -      |
| Adjusted Net Profit | 2,262  | 3,005  | 3,038  | 3,375  |

Source Company data, I-Sec research

### **Exhibit 21: Cashflow statement**

(INR mn, year ending March)

|                                     | FY24A   | FY25E    | FY26E    | FY27E    |
|-------------------------------------|---------|----------|----------|----------|
| Operating Cashflow                  | 14,060  | 10,913   | 19,380   | 19,856   |
| Working Capital Changes             | 1,804   | (3,966)  | (433)    | (3,810)  |
| Capital Commitments                 | (7,468) | (12,000) | (12,000) | (12,000) |
| Free Cashflow                       | 6,592   | (1,087)  | 7,380    | 7,856    |
| Other investing cashflow            | 203     | 758      | 812      | 823      |
| Cashflow from Investing Activities  | (7,265) | (11,242) | (11,188) | (11,177) |
| Issue of Share Capital              | -       | -        | -        | -        |
| Interest Cost                       | (1,307) | (1,064)  | (1,012)  | (1,012)  |
| Inc (Dec) in Borrowings             | (1,556) | (1,835)  | -        | -        |
| Dividend paid                       | -       | -        | -        | -        |
| Others                              | (840)   | (679)    | (723)    | (795)    |
| Cash flow from Financing Activities | (3,703) | (3,577)  | (1,735)  | (1,807)  |
| Chg. in Cash & Bank<br>balance      | 3,093   | (3,907)  | 6,457    | 6,872    |
| Closing cash & balance              | 5,694   | (1,034)  | 5,423    | 12,295   |

Source Company data, I-Sec research

## **Exhibit 22: Key ratios**

(Year ending March)

|                                  | FY24A  | FY25E | FY26E | FY27E |
|----------------------------------|--------|-------|-------|-------|
| Per Share Data (INR)             |        |       |       |       |
| Reported EPS                     | 96.7   | 142.5 | 196.6 | 235.3 |
| Adjusted EPS (Diluted)           | 92.3   | 140.2 | 192.6 | 228.7 |
| Cash EPS                         | 108.2  | 158.8 | 212.7 | 252.8 |
| Dividend per share (DPS)         | 7.5    | 7.5   | 8.0   | 8.8   |
| Book Value per share (BV)        | 365.3  | 498.0 | 682.6 | 902.5 |
| Dividend Payout (%)              | 7.8    | 5.3   | 4.1   | 3.7   |
| Growth (%)                       |        |       |       |       |
| Net Sales                        | (12.3) | 20.3  | 28.7  | 18.8  |
| EBITDA                           | 6.2    | 41.7  | 34.2  | 19.5  |
| EPS (INR)                        | 7.8    | 47.4  | 38.0  | 19.7  |
| Valuation Ratios (x)             |        |       |       |       |
| P/E                              | 91.5   | 62.1  | 45.0  | 37.6  |
| P/CEPS                           | 81.8   | 55.7  | 41.6  | 35.0  |
| P/BV                             | 24.2   | 17.8  | 13.0  | 9.8   |
| EV / EBITDA                      | 60.7   | 42.9  | 31.7  | 26.3  |
| P / Sales                        | 13.6   | 11.3  | 8.8   | 7.4   |
| Dividend Yield (%)               | 0.0    | 0.0   | 0.0   | 0.0   |
| Operating Ratios                 |        |       |       |       |
| Gross Profit Margins (%)         | 47.3   | 48.4  | 45.3  | 44.2  |
| EBITDA Margins (%)               | 22.6   | 26.6  | 27.7  | 27.9  |
| Effective Tax Rate (%)           | 24.6   | 26.0  | 25.9  | 25.9  |
| Net Profit Margins (%)           | 14.4   | 17.7  | 18.9  | 19.1  |
| NWC/Total Assets (%)             | -      | -     | -     | -     |
| Net Debt / Equity (x)            | 0.2    | 0.2   | 0.0   | (0.1) |
| Net Debt / EBITDA (x)            | 0.4    | 0.4   | 0.1   | (0.2) |
| Profitability Ratios             |        |       |       |       |
| RoCE (%)                         | 23.8   | 27.3  | 30.2  | 28.5  |
| RoE (%)                          | 30.6   | 35.2  | 36.2  | 32.0  |
| RoIC (%)                         | 26.4   | 30.0  | 33.7  | 32.4  |
| Fixed Asset Turnover (x)         | 2.5    | 2.4   | 2.3   | 2.1   |
| Inventory Turnover Days          | 55     | 52    | 43    | 41    |
| Receivables Days                 | 55     | 62    | 71    | 68    |
| Payables Days                    | -      | -     | -     | -     |
| Source Company data, I-Sec resea | arch   |       |       |       |

Source Company data, I-Sec research



This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet\_babbar@icicisecuritiesinc.com, Rishi\_agrawal@icicisecuritiesinc.com and Kadambari\_balachandran@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise)
BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return

#### ANALYST CERTIFICATION

I/We, Amit Dixit, PGDM, B.Tech; Mohit Lohia, CA; Pritish Urumkar, MBATech (Finance); authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

#### Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager, Research Analyst and Alternative Investment Fund. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH00000990. ICICI Securities SEBI Registration is INZ000183631 for stock broker. ICICI Securities AIF Trust's SEBI Registration number is IN/AIF3/23-24/1292 ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on <a href="https://www.icicibank.com">www.icicibank.com</a>.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.



Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors.

 $Name of the Compliance of ficer (Research Analyst): Mr. Atul Agrawal, Contact number: 022-40701000, \ \textbf{E-mail Address}: \underline{compliance of ficer@icicisecurities.com}$ 

 $For any queries or grievances: \underline{\textit{Mr. Bhavesh Soni}} \ \ Email \ address: \underline{\textit{headservicequality@icicidirect.com}} \ \ Contact \ \ Number: 18601231122$